Medication info

Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Sungwon Adcock Pharmaceutical Co., Ltd.
Appearance
A hard capsule with white powder inside, white in color.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Expired

MFDS item code 201902107 · Approved 2019.04.05

This product's status changed to Expired on 2024.04.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this drug as pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with Renal Impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = divide the total daily dose into 3 doses BID = divide the total daily dose into 2 doses QD = administer once daily a: The total daily dose (mg/day) should be divided as specified under Administration method. b: An additional dose refers to a dose administered once as a supplement. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12-17 years; use is not recommended.

Ingredients

Manufacturer
Sungwon Adcock Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication treats peripheral and central neuropathic pain in adults. It is also used as an adjunct in patients with epilepsy for partial seizures, showing effectiveness even in cases with secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. In other words, it is used for various neurological-related disorders such as neuralgias, seizures, and fibromyalgia.

How to take

Adult dose

Administer the total daily dose of this drug as pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with Renal Impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = divide the total daily dose into 3 doses BID = divide the total daily dose into 2 doses QD = administer once daily a: The total daily dose (mg/day) should be divided as specified under Administration method. b: An additional dose refers to a dose administered once as a supplement. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12-17 years; use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so it is essential to closely monitor for signs of depression, mood changes, or unusual behavior during treatment. There are contraindications for this medication: individuals allergic to this drug or its components or those with specific genetic conditions such as lactose intolerance should not take it. Diabetic patients may need to adjust their blood sugar control medications due to weight gain after taking this drug. If symptoms of allergic reactions, such as angioedema, appear, the medication should be discontinued immediately. Elderly patients should be cautious of the risk of falls or injuries due to dizziness or drowsiness when taking this medication, and they need to consult a physician if they experience blurred vision or changes in eyesight. Abruptly stopping this medication may cause withdrawal symptoms such as insomnia, headaches, nausea, and anxiety, so it should be tapered gradually according to a doctor's instructions. There is a risk of drug abuse or dependence, so patients with a history of mental illness should be monitored closely and checked for any signs of substance abuse. Patients with cardiovascular disease or kidney dysfunction should be cautious when taking this medication, and especially those with severe congestive heart failure should be administered carefully. Taking this medication with opioid pain relievers may increase central nervous system suppression, leading to a higher risk of respiratory depression, so caution is advised. In the early stages of pregnancy, there may be a risk of congenital malformations to the fetus, thus women who are pregnant or planning to become pregnant must consult their physician and employ effective contraceptive methods. Breastfeeding women should carefully consider the benefits and risks of taking this medication, as it may be transmitted through breast milk and affect the baby. It is safest to avoid activities requiring attention, such as driving or operating machinery, until dizziness or drowsiness fully resolves after taking this medication. In case of overdose, symptoms such as confusion, depression, drowsiness, and seizures may occur, and treatment such as hemodialysis may be required if necessary. This medication should be kept out of reach of children, and caution should be exercised as transferring it to a different container may alter its quality.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 192 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • pain
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysfunction
  • restlessness
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbance
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myopathy
  • reduced reflexes
  • movement disorders
  • psychomotor agitation
  • positional vertigo
  • hyperesthesia
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • psychomotor retardation
  • olfactory disturbance
  • taste loss
  • writing impairment
  • blurred vision
  • diplopia
  • loss of indirect vision
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • conjunctival swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • visual brightness
  • dizziness
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus dysrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • difficulty breathing
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urine
  • kidney failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbance
  • falling
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • seizure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, in a cool place between 15 to 30 degrees Celsius. Storing it this way will help maintain the medication's efficacy for a longer time.

Appearance and packaging

Appearance

A hard capsule with white powder inside, white in color.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.